vimarsana.com
Home
Live Updates
Abelacimab Demonstrates Significant Reduction in Bleeding vs
Abelacimab Demonstrates Significant Reduction in Bleeding vs
Abelacimab Demonstrates Significant Reduction in Bleeding vs Rivaroxaban in Patients With Atrial Fibrillation
The AZALEA-TIMI 71 randomized trial evaluated the safety and tolerability of 2 blinded doses of the novel factor XI inhibitor abelacimab compared with open-label rivaroxaban.
Related Keywords
Massachusetts ,
United States ,
Philadelphia ,
Pennsylvania ,
Boston ,
American ,
,
Cardiovascular Division At Brigham ,
American Heart Association ,
Harvard Medical School ,
Data Monitoring Committee ,
Cardiovascular Division ,
Scientific Sessions ,
Anthos Therapeutics ,